Robert Seder
Overview
Explore the profile of Robert Seder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sutton M, Bucsan A, Lehman C, Kamath M, Pokkali S, Magnani D, et al.
Front Immunol
. 2024 Mar;
15:1359679.
PMID: 38529287
Understanding the immunological control of pathogens requires a detailed evaluation of the mechanistic contributions of individual cell types within the immune system. While knockout mouse models that lack certain cell...
2.
Jongo S, Church L, Milando F, Qassim M, Schindler T, Rashid M, et al.
J Clin Invest
. 2024 Jan;
134(6).
PMID: 38194272
BACKGROUNDSanaria PfSPZ Vaccine, composed of attenuated Plasmodium falciparum (Pf) sporozoites (SPZ), protects against malaria. We conducted this clinical trial to assess the safety and efficacy of PfSPZ Vaccine in HIV-positive...
3.
Malewana R, Stalls V, May A, Lu X, Martinez D, Schafer A, et al.
bioRxiv
. 2024 Jan;
PMID: 38187726
Immunization with mRNA or viral vectors encoding spike with diproline substitutions (S-2P) has provided protective immunity against severe COVID-19 disease. How immunization with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)...
4.
Sutton M, Bucsan A, Lehman C, Kamath M, Pokkali S, Magnani D, et al.
bioRxiv
. 2024 Jan;
PMID: 38187627
Understanding the immunological control of pathogens requires a detailed evaluation of the mechanistic contributions of individual cell types within the immune system. While knockout mouse models that lack certain cell...
5.
Li D, Martinez D, Schafer A, Chen H, Barr M, Sutherland L, et al.
Nat Commun
. 2022 Oct;
13(1):6309.
PMID: 36274085
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that...
6.
Miner M, Hatherill M, Mave V, Gray G, Nachman S, Read S, et al.
Lancet HIV
. 2022 Oct;
9(11):e791-e800.
PMID: 36240834
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis...
7.
Waickman A, Victor K, Newell K, Li T, Friberg H, Foulds K, et al.
JCI Insight
. 2022 Jun;
7(13).
PMID: 35653196
Vaccine-elicited SARS-CoV-2 antibody responses are an established correlate of protection against viral infection in humans and nonhuman primates. However, it is less clear that vaccine-induced immunity is able to limit...
8.
Li D, Martinez D, Schafer A, Chen H, Barr M, Sutherland L, et al.
bioRxiv
. 2022 Feb;
PMID: 35118474
Coronavirus vaccines that are highly effective against SARS-CoV-2 variants are needed to control the current pandemic. We previously reported a receptor-binding domain (RBD) sortase A-conjugated ferritin nanoparticle (RBD-scNP) vaccine that...
9.
Diamond M, Halfmann P, Maemura T, Iwatsuki-Horimoto K, Iida S, Kiso M, et al.
Res Sq
. 2022 Jan;
PMID: 34981044
Despite the development and deployment of antibody and vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein jeopardize their efficacy. The recent emergence of...
10.
Wu K, Choi A, Koch M, Elbashir S, Ma L, Lee D, et al.
Vaccine
. 2021 Nov;
39(51):7394-7400.
PMID: 34815117
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy...